YUKI INOMOTO

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Several clinically approved recombinant erythropoi-etin (rEPO) preparations, such as epoetin-β, epoetin-δ and the epoetin-α derivative, darbepoetin-α, have been commercially produced. Since the expiration of patent protection, a number of novel rEPO biosimilars have been approved on the world market. In 2010, epoetin-κ, which is biosimilar to epoetin-α, was(More)
  • 1